2022
Safety and performance of a novel cerebral embolic protection device for transcatheter aortic valve implantation: the PROTEMBO C Trial.
Jagielak D, Targonski R, Frerker C, Abdel-Wahab M, Wilde J, Werner N, Lauterbach M, Leick J, Grygier M, Misterski M, Erglis A, Narbute I, Witkowski AR, Adam M, Frank D, Gatto F, Schmidt T, Lansky AJ. Safety and performance of a novel cerebral embolic protection device for transcatheter aortic valve implantation: the PROTEMBO C Trial. EuroIntervention 2022, 18: 590-597. PMID: 35608032, PMCID: PMC10241272, DOI: 10.4244/eij-d-22-00238.Peer-Reviewed Original ResearchConceptsTranscatheter aortic valve implantationAortic valve implantationLesion volumeValve implantationTechnical successC trialSingle lesionCerebral embolic protection devicesPerformance endpointBrain diffusion-weighted magnetic resonance imagingLarge single lesionsPrimary safety endpointBrain lesion volumeDiffusion-weighted magnetic resonance imagingCerebral protection systemSingle-arm studyEmbolic protection devicesPrimary performance endpointRate of deathMagnetic resonance imagingTAVI casesTAVI patientsVARC-2Cerebrovascular eventsPrimary endpoint
2013
Impact of bifurcation target lesion on angiographic, electrocardiographic, and clinical outcomes of patients undergoing primary percutaneous coronary intervention (from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction [HORIZONS-AMI] trial).
Dudek D, Mehran R, Dziewierz A, Brener SJ, Rakowski T, Brzezinski M, Brodie BR, Xu K, Fahy M, Lansky AJ, Zmudka K, Stone GW. Impact of bifurcation target lesion on angiographic, electrocardiographic, and clinical outcomes of patients undergoing primary percutaneous coronary intervention (from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction [HORIZONS-AMI] trial). EuroIntervention 2013, 9: 817-23. PMID: 24280158, DOI: 10.4244/eijv9i7a135.Peer-Reviewed Original ResearchConceptsST-segment elevation myocardial infarctionPercutaneous coronary interventionPrimary percutaneous coronary interventionCoronary interventionClinical outcomesTarget lesionsLow left ventricular ejection fractionPost-percutaneous coronary interventionLeft ventricular ejection fractionCore laboratory assessmentHigher contrast loadHORIZONS-AMI trialTarget vessel revascularisationProbable stent thrombosisST-segment resolutionElevation myocardial infarctionVentricular ejection fractionCore laboratory analysisRate of deathBTL groupHORIZONS-AMIVessel revascularisationInfarct arteryBaseline characteristicsContrast load
2012
Long-Term Prognosis of Patients Presenting With ST-Segment Elevation Myocardial Infarction With No Significant Coronary Artery Disease (from The HORIZONS-AMI Trial)
Larsen AI, Nilsen DW, Yu J, Mehran R, Nikolsky E, Lansky AJ, Caixeta A, Parise H, Fahy M, Cristea E, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Stone GW. Long-Term Prognosis of Patients Presenting With ST-Segment Elevation Myocardial Infarction With No Significant Coronary Artery Disease (from The HORIZONS-AMI Trial). The American Journal Of Cardiology 2012, 111: 643-648. PMID: 23261001, DOI: 10.1016/j.amjcard.2012.11.011.Peer-Reviewed Original ResearchConceptsST-segment elevation myocardial infarctionSignificant coronary artery diseaseCoronary artery diseaseElevation myocardial infarctionArtery diseaseMyocardial infarctionGreater left ventricular ejection fractionMajor adverse cardiovascular eventsNet adverse clinical eventsAcute Myocardial Infarction trialObstructive coronary artery diseaseLeft ventricular ejection fractionLower body mass indexBaseline coronary angiogramAdverse cardiovascular eventsCoronary artery bypassMyocardial Infarction trialNormal coronary arteriesOutcomes of patientsAdverse clinical eventsPrognosis of patientsVentricular ejection fractionBody mass indexQuantitative coronary angiographyRate of deathStrategies for Multivessel Revascularization in Patients with Diabetes
Farkouh ME, Domanski M, Sleeper LA, Siami FS, Dangas G, Mack M, Yang M, Cohen DJ, Rosenberg Y, Solomon SD, Desai AS, Gersh BJ, Magnuson EA, Lansky A, Boineau R, Weinberger J, Ramanathan K, Sousa JE, Rankin J, Bhargava B, Buse J, Hueb W, Smith CR, Muratov V, Bansilal S, King S, Bertrand M, Fuster V. Strategies for Multivessel Revascularization in Patients with Diabetes. New England Journal Of Medicine 2012, 367: 2375-2384. PMID: 23121323, DOI: 10.1056/nejmoa1211585.Peer-Reviewed Original ResearchConceptsPercutaneous coronary interventionCoronary artery diseaseMultivessel coronary artery diseaseDrug-eluting stentsCABG groupPCI groupArtery diseaseMyocardial infarctionMedical therapyMean ageAdvanced coronary artery diseaseLow-density lipoprotein cholesterolAggressive medical therapyBenefit of CABGComposite of deathCoronary artery bypassNonfatal myocardial infarctionPatients' mean ageThree-vessel diseaseSystolic blood pressurePrimary outcome measureRate of deathMultivessel revascularizationNonfatal strokeCoronary intervention
2011
Radial access in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty in acute myocardial infarction: the HORIZONS-AMI trial.
Généreux P, Mehran R, Palmerini T, Caixeta A, Kirtane AJ, Lansky AJ, Brodie BR, Witzenbichler B, Mockel M, Guagliumi G, Peruga JZ, Dudek D, Fahy MP, Dangas G, Stone GW. Radial access in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty in acute myocardial infarction: the HORIZONS-AMI trial. EuroIntervention 2011, 7: 905-16. PMID: 22157475, DOI: 10.4244/eijv7i8a144.Peer-Reviewed Original ResearchConceptsST-segment elevation myocardial infarctionPrimary percutaneous coronary interventionPrimary PCIHORIZONS-AMI trialElevation myocardial infarctionMajor bleedingMyocardial infarctionTF approachMajor adverse cardiovascular eventsNet adverse clinical eventsAdverse cardiovascular eventsEvent-free survivalAdverse clinical eventsPercutaneous coronary interventionImproved clinical outcomesAcute myocardial infarctionOne-year ratesRate of deathPaucity of dataComposite deathHORIZONS-AMICardiovascular eventsPrimary angioplastyAnticoagulation regimensCoronary intervention
2009
5-Year Clinical Outcomes After Sirolimus-Eluting Stent Implantation Insights From a Patient-Level Pooled Analysis of 4 Randomized Trials Comparing Sirolimus-Eluting Stents With Bare-Metal Stents
Caixeta A, Leon MB, Lansky AJ, Nikolsky E, Aoki J, Moses JW, Schofer J, Morice MC, Schampaert E, Kirtane AJ, Popma JJ, Parise H, Fahy M, Mehran R. 5-Year Clinical Outcomes After Sirolimus-Eluting Stent Implantation Insights From a Patient-Level Pooled Analysis of 4 Randomized Trials Comparing Sirolimus-Eluting Stents With Bare-Metal Stents. Journal Of The American College Of Cardiology 2009, 54: 894-902. PMID: 19712798, DOI: 10.1016/j.jacc.2009.04.077.Peer-Reviewed Original ResearchConceptsBare metal stentsTarget vessel revascularizationStent thrombosisRate of deathMyocardial infarctionVessel revascularizationPooled analysisAcademic Research Consortium definitionsPatient-level pooled analysisDrug-eluting stent implantationArterial healing responseComposite of deathProbable stent thrombosisLong-term safetyDrug-eluting stentsLate stent thrombosisClinical outcomesRandomized trialsStent implantationSuperior efficacyBMS groupThrombosisHealing responseSES groupStents
2003
Outcomes of optimal or “stent-like”balloon angioplasty in acutemyocardial infarction: the CADILLAC trial
Cox DA, Stone GW, Grines CL, Stuckey T, Cohen DJ, Tcheng JE, Garcia E, Guagliumi G, Iwaoka RS, Fahy M, Turco M, Lansky AJ, Griffin JJ, Mehran R, Investigators C. Outcomes of optimal or “stent-like”balloon angioplasty in acutemyocardial infarction: the CADILLAC trial. Journal Of The American College Of Cardiology 2003, 42: 971-977. PMID: 13678914, DOI: 10.1016/s0735-1097(03)00911-2.Peer-Reviewed Original ResearchConceptsPercutaneous transluminal coronary angioplastyAcute myocardial infarctionTarget vessel revascularizationIschemic target vessel revascularizationRoutine stentingRoutine stent placementStent implantationStent placementPrimary percutaneous transluminal coronary angioplastyComposite adverse event rateLate Angioplasty Complications (CADILLAC) trialRoutine stent implantationAdverse event ratesTransluminal coronary angioplastyRelevant treatment modalitiesRate of deathCADILLAC trialControlled AbciximabEligible lesionsAngiographic restenosisVessel revascularizationComplications TrialCoronary angioplastyDiameter stenosisPTCA results
2002
Comparison of Angioplasty with Stenting, with or without Abciximab, in Acute Myocardial Infarction
Stone GW, Grines CL, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Carroll JD, Rutherford BD, Lansky AJ. Comparison of Angioplasty with Stenting, with or without Abciximab, in Acute Myocardial Infarction. New England Journal Of Medicine 2002, 346: 957-966. PMID: 11919304, DOI: 10.1056/nejmoa013404.Peer-Reviewed Original ResearchMeSH KeywordsAbciximabAdultAgedAged, 80 and overAngioplasty, Balloon, CoronaryAntibodies, MonoclonalCombined Modality TherapyCoronary AngiographyFemaleHumansImmunoglobulin Fab FragmentsMaleMiddle AgedMyocardial InfarctionMyocardial ReperfusionPlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexProspective StudiesRecurrenceStentsStrokeConceptsPrimary percutaneous transluminal coronary angioplastyAcute myocardial infarctionPercent of patientsPrimary end pointInfarct-related arteryRate of deathMyocardial infarctionAbciximab therapyReperfusion strategyPlatelet glycoprotein IIb/IIIa inhibitorsGlycoprotein IIb/IIIa inhibitorsTarget vesselIIb/IIIa inhibitorsPercutaneous transluminal coronary angioplastyEnd pointComposite of deathTarget vessel revascularizationIschemia-driven revascularizationTransluminal coronary angioplastyComparison of AngioplastyAbciximab useRecurrent ischemiaExperienced centersCoronary angioplastyCoronary stenting